Literature DB >> 18065802

Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death.

Areef Ishani1, Craig A Solid, Eric D Weinhandl, David T Gilbertson, Robert N Foley, Allan J Collins.   

Abstract

BACKGROUND: A proportion of haemodialysis patients experience periods below target haemoglobin levels due to longer time required to reach the target or to haemoglobin level variability. We aimed to determine the consequences associated with cumulative number of months below target haemoglobin concentrations.
METHODS: We constructed an incident cohort including patients whose day 91 after dialysis initiation fell between 1 January and 31 December 2002. Haemoglobin concentration, erythropoiesis-stimulating agent dose, comorbid condition and hospitalization data were obtained from Medicare claims. Patients were classified by 0, 1, 2 or 3 months with haemoglobin concentration below the K/DOQI target (11 g/dL). Using an inverse probability weighted marginal structural model to adjust for time-varying factors associated with haemoglobin concentration, we determined the association between number of months below target and subsequent risk for hospitalization and mortality.
RESULTS: The final cohort included 54 328 patients who met criteria. Those with more months below haemoglobin target were less likely to have received intravenous iron. More months below target were associated with increased risk of hospitalization (RR 1.70, 95% CI 1.63-1.76) and mortality (RR 2.48, 95% CI 2.28-2.69).
CONCLUSIONS: Future interventions should focus on modifiable factors associated with greater time below target haemoglobin concentrations to determine whether altering the time below target can alter the risk of hospitalizations or mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18065802     DOI: 10.1093/ndt/gfm845

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  13 in total

1.  The effect of altitude change on anemia treatment response in hemodialysis patients.

Authors:  M Alan Brookhart; Brian D Bradbury; Jerry Avorn; Sebastian Schneeweiss; Wolfgang C Winkelmayer
Journal:  Am J Epidemiol       Date:  2011-02-23       Impact factor: 4.897

2.  Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis.

Authors:  Nicholas M Selby; Sally A Fonseca; Richard J Fluck; Maarten W Taal
Journal:  Perit Dial Int       Date:  2011-11-01       Impact factor: 1.756

3.  Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Authors:  Roberto Minutolo; Paolo Chiodini; Bruno Cianciaruso; Andrea Pota; Vincenzo Bellizzi; Deborah Avino; Sara Mascia; Simona Laurino; Valerio Bertino; Giuseppe Conte; Luca De Nicola
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

4.  Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.

Authors:  Brian D Bradbury; Mark D Danese; Michelle Gleeson; Cathy W Critchlow
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

Review 5.  Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.

Authors:  Monique P Curran; Paul L McCormack
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.

Authors:  Janice P Lea; Keith Norris; Lawrence Agodoa
Journal:  Am J Nephrol       Date:  2008-04-24       Impact factor: 3.754

7.  The effect of Vitamin D administration on treatment of anemia in end-stage renal disease patients with Vitamin D deficiency on hemodialysis: A placebo-controlled, double-blind clinical trial.

Authors:  Afsoon Emami Naini; Zahra Parin Hedaiati; Danial Gholami; Amir Hossein Pezeshki; Firoozeh Moinzadeh
Journal:  J Res Med Sci       Date:  2015-08       Impact factor: 1.852

8.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01

9.  Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.

Authors:  Silvia Soffritti; Giorgia Russo; Stefano Cantelli; Giuseppe Gilli; Luigi Catizone
Journal:  BMC Nephrol       Date:  2009-10-24       Impact factor: 2.388

10.  Does erythropoietin cause hemoglobin variability--is it 'normal'?

Authors:  Ashwani K Gupta; Waseem David
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.